Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $31.00.

Several analysts recently weighed in on the company. Wall Street Zen upgraded Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Weiss Ratings began coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Jefferies Financial Group initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $32.00 price target on the stock. Leerink Partners began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set an “outperform” rating and a $30.00 price objective for the company. Finally, Stifel Nicolaus began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued a “buy” rating and a $28.00 target price on the stock.

Maplight Therapeutics Stock Up 3.5%

Shares of NASDAQ:MPLT opened at $17.57 on Thursday. The firm has a 50 day moving average price of $18.08. Maplight Therapeutics has a 12 month low of $12.24 and a 12 month high of $21.55. The firm has a market cap of $797.15 million and a PE ratio of -0.47.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Insider Buying and Selling at Maplight Therapeutics

In related news, Director Robert C. Malenka sold 7,039 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.02, for a total transaction of $126,842.78. Following the sale, the director owned 358,234 shares in the company, valued at $6,455,376.68. The trade was a 1.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 41,438 shares of company stock worth $762,687.

Institutional Trading of Maplight Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC acquired a new position in shares of Maplight Therapeutics in the fourth quarter valued at approximately $6,835,000. Blue Owl Capital Holdings LP acquired a new stake in Maplight Therapeutics during the 4th quarter worth approximately $5,745,000. Finally, Strs Ohio bought a new stake in Maplight Therapeutics during the 4th quarter worth approximately $53,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.